Vulcan Two Group plc (LSE: VUL) has signed a five-year licence agreement with a global provider of cloud-based enterprise software to implement a central enterprise resource planning (ERP) system as part of its strategy to build a leading regulated ePharmacy platform in the UK.
The ERP platform will consolidate the Group's key operational processes into a single managed system designed to support the company's growth strategy. The software incorporates technologies including generative artificial intelligence, agentic AI, machine learning and advanced analytics. Implementation will be delivered by one of the provider's consultancy partners and overseen internally by Vulcan Two's recently appointed ERP Director.
This agreement follows the company's announcement on 26 February 2026 that it had conditionally raised GBP40m to acquire three companies in the ePharmacy sector, as outlined in its Admission Document published on 27 February 2026. Directors said the chosen platform was selected following detailed scoping work and is intended to support the group's enlarged operations following the proposed acquisitions.
The ERP system will be introduced in phases to ensure integration across the group while minimising disruption to underlying businesses. Under the terms of the agreement, Vulcan Two will pay an annual subscription fee of GBP80,000, rising to GBP100,000 over the five-year term. The company also expects to pay consultancy fees of approximately GBP765,000 during 2026 for the system's implementation, with most of the expenditure expected to be capitalised as an intangible asset.
Vulcan Two signs five-year ERP licence agreement to support ePharmacy expansion
SportsMed Physical Therapy named Physical Therapy Company of the Year
Ensorcell adds new senior leadership team members
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards